6 results
Study goal is to compare the performance of the Absorb bioresorbable scaffold with a metallic drug eltuting stent in the STEMI patient.
The main objective of this study is to assess whether in-hospital administration of empagliflozin results in improvement in HF-related outcomes in patients hospitalised for acute heart failure (de novo or decompensated chronic HF) and after initial…
To investigate the potential of preoperative initiation (7 days) and perioperative continuation (until day 2 after surgery) of empagliflozin 10 mg daily to reduce the acute kidney injury marker neutrophil gelatinase-associated lipocalin (NGAL) on…
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics
Primary Objective: to determine the status of screw degradation, osseous replacement and host response of a biodegradable self-reinforcedTM poly 96L/4D lactide copolymer and βTCP biocomposite interference screw at five years after an ACL…
The purpose of the current investigation is therefore to prove the short-term equivalence and long-term benefit of the ABSORB scaffold over a Xience in patients at high risk of restenosis or with complex lesion(s).Diabetic substudyTo assess the…